SNRIs

High-yield Verified · Jul 2026

Prototype: venlafaxine

Serotonin-norepinephrine reuptake inhibitors — the SSRI’s dual-action cousin, useful in depression and chronic pain.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 Adding a second neurotransmitter

SSRIs (see that page) lift mood by raising serotonin alone. SNRIs go one step further: they block the reuptake of both serotonin (SERT) and norepinephrine (NET), so *two* mood-and-pain neurotransmitters build up in the synapse. That dual action gives them a second, distinctive use — because norepinephrine (and serotonin) also dampen pain signals in the spinal cord, SNRIs treat neuropathic pain, fibromyalgia, and diabetic neuropathy in addition to depression and anxiety.

Like all antidepressants, the mood benefit is delayed 2–4 weeks while receptors adapt, and — like the SSRIs — they carry the class boxed warning for suicidality in patients under 25 during early treatment.

Loading diagram…

SNRIs block reuptake of both serotonin and norepinephrine — dual mood + pain effect.

02 The two nursing themes — blood pressure and discontinuation

The norepinephrine effect explains a signature adverse effect: dose-dependent hypertension, most notable with venlafaxine — so blood pressure is monitored. (Duloxetine is often chosen when BP is a concern.) Combining an SNRI with other serotonergic drugs (SSRIs, MAOIs, triptans, tramadol, St. John’s wort) risks serotonin syndrome.

The second theme is discontinuation syndrome: stopping abruptly — especially short-half-life venlafaxine — causes dizziness, "brain zaps," flu-like symptoms, and irritability. SNRIs must be tapered, never stopped cold.

Drug names

Generic Brand

venlafaxine Effexor XR

duloxetine Cymbalta

desvenlafaxine Pristiq

Indications

Major depressive disorder & generalized/social anxiety, panic disorder
Neuropathic pain: diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain (duloxetine)
Off-label: PTSD, hot flashes, migraine prevention

Mechanism of action

Inhibit reuptake of both serotonin (SERT) and norepinephrine (NET), increasing their synaptic availability — improving mood/anxiety and, through descending inhibitory pain pathways, relieving neuropathic pain. Norepinephrine reuptake block underlies the blood-pressure effect.

In plain terms

They boost two of the brain’s mood chemicals — serotonin and norepinephrine — which also quiets certain kinds of nerve pain.

Therapeutic effects — what you'll see working

Mood benefit builds over 2–4 weeks (assess adherence and suicidality early); pain relief may appear sooner. The dual mechanism means monitoring both psychiatric response and blood pressure.

Improved mood & anxiety Neuropathic pain relief

Improved mood & anxiety: Raising serotonin and norepinephrine relieves depression and anxiety over weeks, comparable to SSRIs.
Neuropathic pain relief: Enhanced descending inhibition in the spinal cord reduces diabetic-neuropathy and fibromyalgia pain — a benefit SSRIs largely lack.

Adverse effects

The serotonin effects mirror SSRIs (GI, sexual, serotonin syndrome); the added norepinephrine effect brings hypertension and activation. Discontinuation is the practical pitfall.

Common

Nausea, headache, insomnia, dry mouth, sweating, sexual dysfunction, dose-dependent hypertension (venlafaxine).

Blood-pressure elevation rises with venlafaxine dose — monitor BP. Nausea and activation often ease over the first weeks.

Serious Report immediately

Serotonin syndrome; discontinuation syndrome (abrupt stop); hyponatremia (SIADH); hepatotoxicity (duloxetine); increased bleeding with NSAIDs/anticoagulants.

Serotonin syndrome (agitation, tremor, hyperthermia, clonus) can occur with other serotonergic drugs. Abrupt discontinuation — especially venlafaxine — causes a distinct withdrawal (dizziness, "brain zaps"); always taper. Serotonin also affects platelets, raising bleeding risk with NSAIDs/anticoagulants.

■ Boxed warning · suicidality

Increased suicidal thinking/behavior in children, adolescents, and young adults (< 25), especially early in treatment.

Monitor closely for worsening depression, agitation, or suicidal ideation during the first weeks and after dose changes — the same class boxed warning as SSRIs.

Interactions

MAOIs and other serotonergics (SSRIs, triptans, tramadol, linezolid, St. John’s wort) drug

Additive serotonin → risk of serotonin syndrome; separate MAOIs by ≥ 14 days.

Contraindications

The contraindications are the serotonergic-combination dangers and the states worsened by added norepinephrine.

Concurrent MAOIs (or within 14 days)

The combination can cause fatal serotonin syndrome — separate by at least 2 weeks.

Uncontrolled hypertension (venlafaxine); uncontrolled narrow-angle glaucoma (duloxetine) use caution

The norepinephrine effect raises BP and can raise intraocular pressure.

Significant hepatic impairment / heavy alcohol use (duloxetine) use caution

Duloxetine is hepatically cleared and can be hepatotoxic.

When to hold

Assess before giving — these findings mean hold the dose and act.

Rising or uncontrolled blood pressure (dose-dependent, especially venlafaxine)

Monitor BP at baseline and with each dose increase; hold and notify for sustained hypertension.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Monitoring

Monitor blood pressure (especially venlafaxine) and watch for suicidality early in therapy.

Why: Norepinephrine reuptake block raises BP dose-dependently; the boxed warning requires close early monitoring.

Screen the med list for other serotonergic drugs (triptans, tramadol, MAOIs, St. John’s wort).

Why: Combinations risk serotonin syndrome.

Patient teaching

Never stop abruptly — taper with the prescriber; expect 2–4 weeks for full mood benefit.

Why: Abrupt discontinuation (especially venlafaxine) causes withdrawal; the delayed onset must be anticipated so patients don’t quit early.

Sources

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.